Hepatitis C Virus
Scientists at University of Delhi target hepatitis C virus
Published in Hospital Business Week, April 13th, 2008
"This study aimed to assess the safety and efficacy of two different regimens of peg-IFN alfa-2b, in combination with ribavirin, in genotype 3 patients. A total of 103 liver biopsy-proven chronic HCV patients with genotype 3, having alanine aminotransferase levels > 1.2 x ULN and positive HCV-RNA were randomized into two groups: group...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
More Articles from Hospital Business Week
- AcroMetrix
AcroMetrix Announces Launch of First Liquid MRSA Positive Control - Actuate Corporation
Presbyterian Healthcare Services Relies on Actuate-Based Rich Internet Applications to Focus Staff, Improve Patient Loyalty and Exceed Regulated Performance Thresholds - Agency for Healthcare Research & Quality
AHRQ's 2007 State Snapshots Provide Broader Portraits of State-By-State Health Care Performance - Alliant Healthcare Products
Premier Purchasing Partners Awards Cardiac Disposable Contract to Veteran-Owned, Alliant Healthcare Products - AmerisourceBergen Corporation
American Health Packaging Announces a Recall of Approximately 1,400 Units of Heparin Sodium Vial Products as Part of Broader Baxter Recall - Anesthesia
Smiths Medical and MedAssets Supply Chain Systems Sign Multi-Year Supply Agreement - More from this issue of Hospital Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
